Study progress on cerebral small vessel disease complicated with neurodegenerative disorders in central nervous system

doi:10.16150/j.1671-2870.2022.05.018

Abstract

Abstract:

There is a common molecular basis and neurobiological mechanism in the pathogenesis of cerebral small vessel disease (CSVD) and degenerative diseases in central nervous system (such as Alzheimer′s disease, Parkinson′s disease and frontotemporal degeneration), including hypoxia, vascular endothelial dysfunction, impairment of cerebrovascular vasomotor response, dysfunction of blood-brain barrier and impairment of glial lymphatic pathway. The CSVD patients complicated with the neurodegenerative diseases often show different clinical phenotypes, disease process and outcome from neurodegenerative diseases. The cerebrospinal fluid biomarkers show certain value in the diagnosis of CSVD complicated with neurodegenerative diseases. The brain network has a certain application prospect in comprehensive study of the relationship between CSVD and neurodegenerative diseases. In the future, the treatment of neurodegenerative diseases focusing on vascular neuroinflammatory model will show broad prospects.

Key words: Cerebral small vessel disease, Alzheimer′s disease, Parkinson′s disease, Biomarker, Brain network

CLC Number:

R743
R742

WU Dongdong, CHEN Yuhui, LIU Fang, LIU Yinhong, JIANG Jingwen. Study progress on cerebral small vessel disease complicated with neurodegenerative disorders in central nervous system[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 644-649.

Figures/Tables 1

References 47

[1]	Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications[J]. Lancet Neurol, 2019, 18(7):684-696. doi: S1474-4422(19)30079-1 pmid: 31097385
[2]	Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration[J]. Lancet Neurol, 2013, 12(8):822-838. doi: 10.1016/S1474-4422(13)70124-8 pmid: 23867200
[3]	Debette S, Schilling S, Duperron MG, et al. Clinical significance of magnetic resonance imaging markers of vascular brain injury: A systematic review and meta-analysis[J]. JAMA Neurol, 2019, 76(1):81-94. doi: 10.1001/jamaneurol.2018.3122 pmid: 30422209
[4]	Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases[J]. Nat Neurosci, 2018, 21(10):1332-1340. doi: 10.1038/s41593-018-0235-9 pmid: 30250260
[5]	Wang Z, Yang D, Zhang X, et al. Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons[J]. PLoS One, 2011, 6(4):e19229. doi: 10.1371/journal.pone.0019229 URL
[6]	Fang H, Zhang LF, Meng FT, et al. Acute hypoxia promote the phosphorylation of tau via ERK pathway[J]. Neurosci Lett, 2010, 474(3):173-177. doi: S0304-3940(10)00334-4 pmid: 20304032
[7]	Kahl A, Blanco I, Jackman K, et al. Cerebral ischemia induces the aggregation of proteins linked to neurodegenerative diseases[J]. Sci Rep, 2018, 8(1):2701. doi: 10.1038/s41598-018-21063-z pmid: 29426953
[8]	Sarkar S, Raymick J, Mann D, et al. Neurovascular changes in acute, sub-acute and chronic mouse models of Parkinson′s disease[J]. Curr Neurovasc Res, 2014, 11(1):48-61. pmid: 24274908
[9]	Lyros E, Bakogiannis C, Liu Y, et al. Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer′s disease[J]. Curr Alzheimer Res, 2014, 11(1):18-26. doi: 10.2174/1567205010666131119235254 URL
[10]	Koizumi K, Wang G, Park L. Endothelial dysfunction and amyloid-beta-induced neurovascular alterations[J]. Cell Mol Neurobiol, 2016, 36(2):155-165. doi: 10.1007/s10571-015-0256-9 pmid: 26328781
[11]	Buratti L, Balestrini S, Altamura C, et al. Markers for the risk of progression from mild cognitive impairment to Alzheimer′s disease[J]. J Alzheimers Dis, 2015, 45(3):883-890. doi: 10.3233/JAD-143135 pmid: 25633680
[12]	Camargo CH, Martins EA, Lange MC, et al. Abnormal cerebrovascular reactivity in patients with Parkinson′s disease[J]. Parkinsons Dis, 2015, 2015:523041.
[13]	Iadecola C. Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer′s dementia[J]. Cell Mol Neurobiol, 2003, 23(4-5):681-689. doi: 10.1023/A:1025092617651 URL
[14]	van Beek AH, Claassen JA. The cerebrovascular role of the cholinergic neural system in Alzheimer′s disease[J]. Behav Brain Res, 2011, 221(2):537-542. doi: 10.1016/j.bbr.2009.12.047 URL
[15]	Müller ML, Bohnen NI. Cholinergic dysfunction in Parkinson′s disease[J]. Curr Neurol Neurosci Rep, 2013, 13(9):377. doi: 10.1007/s11910-013-0377-9 URL
[16]	Thal DR. The pre-capillary segment of the blood-brain barrier and its relation to perivascular drainage in Alzheimer′s disease and small vessel disease[J]. ScientificWorldJournal, 2009, 9:557-563. doi: 10.1100/tsw.2009.72 URL
[17]	Utter S, Tamboli IY, Walter J, et al. Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes[J]. J Neuropathol Exp Neurol, 2008, 67(9):842-856. doi: 10.1097/NEN.0b013e3181836a71 URL
[18]	Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease[J]. Cold Spring Harb Perspect Med, 2012, 2(3):a006312.
[19]	Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders[J]. Lancet Neurol, 2018, 17(11):1016-1024. doi: S1474-4422(18)30318-1 pmid: 30353860
[20]	Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer′s disease[J]. Alzheimers Dement., 2018, 14(4):535-562. doi: 10.1016/j.jalz.2018.02.018 URL
[21]	Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association[J]. Stroke, 2011, 42(9):2672-2713. doi: 10.1161/STR.0b013e3182299496 pmid: 21778438
[22]	Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer′s disease--lessons from pathology[J]. BMC Med, 2014, 12:206. doi: 10.1186/s12916-014-0206-2 URL
[23]	Soldan A, Pettigrew C, Zhu Y, et al. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease[J]. Neurology, 2020, 94(9):e950-e960. doi: 10.1212/WNL.0000000000008864 URL
[24]	Carmichael O, Schwarz C, Drucker D, et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative[J]. Arch Neurol, 2010, 67(11):1370-1378. doi: 10.1001/archneurol.2010.284 URL
[25]	Esiri MM, Joachim C, Sloan C, et al. Cerebral subcortical small vessel disease in subjects with pathologically confirmed Alzheimer disease: a clinicopathologic study in the Oxford Project to Investigate Memory and Ageing (OPTIMA)[J]. Alzheimer Dis Assoc Disord, 2014, 28(1):30-35. doi: 10.1097/WAD.0b013e31829b72f1 URL
[26]	Ortner M, Kurz A, Alexopoulos P, et al. Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer′s disease[J]. Biol Psychiatry, 2015, 77(8):704-710. doi: 10.1016/j.biopsych.2014.01.019 URL
[27]	Stefaniak JD, Su L, Mak E, et al. Cerebral small vessel disease in middle age and genetic predisposition to late-onset Alzheimer′s disease[J]. Alzheimers Dement, 2018, 14(2):253-258. doi: S1552-5260(17)33809-8 pmid: 29156222
[28]	Raz N, Yang Y, Dahle CL, et al. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants[J]. Biochim Biophys Acta, 2012, 1822(3):361-369. doi: 10.1016/j.bbadis.2011.08.007 pmid: 21889590
[29]	Groot C, Sudre CH, Barkhof F, et al. Clinical phenotype, atrophy, and small vessel disease in APOE ε2 carriers with Alzheimer disease[J]. Neurology, 2018, 91(20):e1851-e1859. doi: 10.1212/WNL.0000000000006503 URL
[30]	Ferreira D, Shams S, Cavallin L, et al. The contribution of small vessel disease to subtypes of Alzheimer′s disease: a study on cerebrospinal fluid and imaging biomarkers[J]. Neurobiol Aging, 2018, 70:18-29. doi: S0197-4580(18)30196-9 pmid: 29935417
[31]	Antonini A, Vitale C, Barone P, et al. The relationship between cerebral vascular disease and parkinsonism: The VADO study[J]. Parkinsonism Relat Disord, 2012, 18(6):775-780. doi: 10.1016/j.parkreldis.2012.03.017 URL
[32]	Malek N, Lawton MA, Swallow DM, et al. Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson′s disease[J]. Mov Disord, 2016, 31(10):1518-1526. doi: 10.1002/mds.26698 URL
[33]	Shibata K, Sugiura M, Nishimura Y, et al. The effect of small vessel disease on motor and cognitive function in Parkinson′s disease[J]. Clin Neurol Neurosurg, 2019, 182:58-62. doi: 10.1016/j.clineuro.2019.04.029 URL
[34]	Seelaar H, Rohrer JD, Pijnenburg YA, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review[J]. J Neurol Neurosurg Psychiatry, 2011, 82(5):476-486. doi: 10.1136/jnnp.2010.212225 pmid: 20971753
[35]	Thal DR, von Arnim CA, Griffin WS, et al. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies[J]. J Neural Transm (Vienna), 2015, 122(7):1007-1018.
[36]	de Guio F, Jouvent E, Biessels GJ, et al. Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease[J]. J Cereb Blood Flow Metab, 2016, 36(8):1319-1337. doi: 10.1177/0271678X16647396 URL
[37]	Bjerke M, Zetterberg H, Edman A, et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer′s disease[J]. J Alzheimers Dis, 2011, 27(3):665-676. doi: 10.3233/JAD-2011-110566 pmid: 21860087
[38]	Jonsson M, Zetterberg H, van Straaten E, et al. Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study[J]. Eur J Neurol. 2010 Mar, 17(3):377-382. doi: 10.1111/j.1468-1331.2009.02808.x pmid: 19845747
[39]	Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry, 2019, 90(8):870-881. doi: 10.1136/jnnp-2018-320106 pmid: 30967444
[40]	Ohrfelt A, Andreasson U, Simon A, et al. Screening for new biomarkers for subcortical vascular dementia and Alzheimer′s disease[J]. Dement Geriatr Cogn Dis Extra, 2011, 1(1):31-42. doi: 10.1159/000323417 pmid: 22163231
[41]	Pasi M, van Uden IW, Tuladhar AM, et al. White matter microstructural damage on diffusion tensor imaging in cerebral small vessel disease: Clinical Consequences[J]. Stroke, 2016, 47(6):1679-1684. doi: 10.1161/STROKEAHA.115.012065 pmid: 27103015
[42]	Tuladhar AM, van Uden IW, Rutten-Jacobs LC, et al. Structural network efficiency predicts conversion to dementia[J]. Neurology, 2016, 86(12):1112-1119. doi: 10.1212/WNL.0000000000002502 pmid: 26888983
[43]	Baggio HC, Segura B, Sala-Llonch R, et al. Cognitive impairment and resting-state network connectivity in Parkinson′s disease[J]. Hum Brain Mapp, 2015, 36(1):199-212. doi: 10.1002/hbm.22622 URL
[44]	Ding W, Cao W, Wang Y, et al. Altered functional connectivity in patients with subcortical vascular cognitive impairment: A resting-state functional magnetic resonance imaging study[J]. PLoS One, 2015, 10(9):e0138180. doi: 10.1371/journal.pone.0138180 URL
[45]	Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer′s disease and other disorders[J]. Nat Rev Neurosci, 2011, 12(12):723-738.
[46]	Garry PS, Ezra M, Rowland MJ, et al. The role of the nitric oxide pathway in brain injury and its treatment--from bench to bedside[J]. Exp Neurol, 2015, 263:235-243. doi: 10.1016/j.expneurol.2014.10.017 pmid: 25447937
[47]	Spuch C, Antequera D, Portero A, et al. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer′s disease[J]. Biomaterials, 2010, 31(21):5608-5618. doi: 10.1016/j.biomaterials.2010.03.042 URL